NEWS RELEASES

Search all of our news releases here.

Try these: Jeff GalvinC. David PauzaHIVFDAAmerican Gene Technologies

American Gene Technologies To Attend 2019 J.P. Morgan Healthcare Conference

American Gene Technologies To Attend 2019 J.P. Morgan Healthcare Conference

Jan 7, 2019

ROCKVILLE, MD, UNITED STATES, January 7, 2019 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 7-10 in San Francisco, California. American Gene Technologies invitation to attend the…

Read More
The U.S. Food and Drug Administration (FDA) received orphan-drug designation #DRU-2018-6572 for the treatment of phenylketonuria (PKU) using its proprietary, lentiviral vector based technology

American Gene Technologies Granted FDA Orphan Drug Designation For Phenylketonuria

Oct 18, 2018

ROCKVILLE, MD, UNITED STATES, October 18, 2018 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy company in the discovery and development of lentiviral vector based therapeutics, announces that the U.S. Food and Drug Administration (FDA) received orphan-drug designation #DRU-2018-6572 for the treatment…

Read More
Chief Science Officer C. David Pauza, Ph.D. will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa

American Gene Technologies to Present at 2018 Cell and Gene Meeting On The Mesa

Sep 26, 2018

ROCKVILLE, MD, UNITED STATES, September 26, 2018 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Science Officer C. David Pauza, Ph.D. will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, California.…

Read More
Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the Cancer Support Community (CSC)

Immunotherapy CEO Jeff Galvin Joins The Board of Directors of the Cancer Support Community

Sep 6, 2018

ROCKVILLE, MD, UNITED STATES, September 6, 2018 /EINPresswire.com/ — Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the Cancer Support Community (CSC).…

Read More
AGT has received three foundational patents

American Gene Technologies (AGT) Granted Three New Patents in its HIV Cure and Immuno-oncology Programs

Aug 22, 2018

ROCKVILLE, MD, UNITED STATES, August 22, 2018 /EINPresswire.com/ — AGT announces the receipt of three foundational patents. Two new patents focus on the immuno-oncology program and add to AGT’s broad protection for its unique process of activating gamma delta T cells to attack solid tumors…

Read More
AGT CEO and founder Jeff Galvin has been appointed to the Board of Directors of the Maryland Tech Council

American Gene Technologies CEO Jeff Galvin Joins Maryland Tech Council Board of Directors

Aug 20, 2018

ROCKVILLE, MD, UNITED STATES, August 20, 2018 /EINPresswire.com/ — American Gene Technologies International Inc. (AGT)’s CEO and founder Jeff Galvin has been appointed to the Board of Directors of the Maryland Tech Council, the largest Maryland technology trade association, representing over 600 companies across the…

Read More
After Researching Gene and Cell Therapy, AGT's Dr. Redfield Joins CDC

American Gene Technologies Congratulates Robert Redfield, M.D., on His Appointment as Director of the Centers for Disease Control and Prevention

Apr 30, 2018

ROCKVILLE, Md., March 28, 2018 (GLOBE NEWSWIRE) – American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today congratulates Robert R. Redfield, M.D., on his appointment as the Director of the Centers for Disease Control and Prevention (CDC). Dr. Redfield has served as…

Read More
American Gene Technologies announces receipt of a second immuno-oncology patent on the stimulation of gamma delta T cells for treating solid tumors in epithelial cancers

American Gene Technologies Gains Additional Immuno-Oncology Patent

Mar 19, 2018

Novel approach to activating gamma delta T cells shows promise in animal studies — demonstrating efficacy in multiple epithelial solid tumors and metastases ROCKVILLE, Md., March 19, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced…

Read More
AGT's Progress Toward Phase I Clinical Trial of HIV Cure

American Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV cure

Jan 29, 2018

Completes process development for the AGT103-T automated cell manufacturing protocol ROCKVILLE, MD, January 25, 2018 – American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV cure automated cell processing protocol. This completes…

Read More
American Gene Technologies announces the issuance of U.S. Patent No: 9,834,790 dated December 5, 2017, covering methods of treating cancer with AGT’s proprietary viral vector technology

American Gene Technologies Receives U.S. Patent on Novel Immuno-Oncology Methods of Treating Cancer through Activation of Gamma Delta T Cells

Dec 12, 2017

  Patent encompasses AGT’s advanced gene and cell therapy strategy for oncology ROCKVILLE, MD, December 12, 2017 — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced the issuance of U.S. Patent No: 9,834,790 dated December 5, 2017, covering methods…

Read More

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media

AGT on Facebook

Tune in to Cell & Gene: The Podcast and hear Addimmune's Dr. Marcus Conant, a pioneer in HIV research, discuss our innovative cell therapy for HIV. He shares his vision for empowering patients and transforming HIV treatment. loom.ly/96TZ0jU#HIV #celltherapy #biotech ... See MoreSee Less
View on Facebook
M&A has been steady in 2024. We count 47 private & public deals to date totaling $53 billion. 15 have been >$1 billion with cancer, rare disease & cell therapies some of the areas of interest. ... See MoreSee Less
View on Facebook
AGT CEO, Jeff Galvin, had a chat with social media influencer and HIV advocate, Raif Derrazi, to discuss the latest updates on our AGT103-T clinical trials. Dive into the conversation as they shed light on the research and what lies ahead in our mission to find a cure for HIV! loom.ly/jAThqIU#HIV #hivcure #HIVresearch #clinicaltrials ... See MoreSee Less
View on Facebook
Can genetic evidence make drugs more effective? A new study in Nature suggests YES. Drug mechanisms with genetic support have a 2.6x higher chance of success. loom.ly/NxSxjXk#genetics #science #Healthcare ... See MoreSee Less
View on Facebook